Risperdal is an antipsychotic drug that is used to treat delusional psychoses. Dopamine is a vital neurotransmitter that the brain uses which allows a person to experience pleasure and desire. Risperdal acts to reduce the amount of dopamine the brain produces so that a natural balance of chemicals in the brain. This can reduce many psychotic episodes that people experience.
Attorneys for Risperdal victims claim that J&J and Janssen used illegal marketing to promote Risperdal for unapproved uses even after they were aware of the link to gynecomastia, and it failed to adequately warn of those risks.
In 2001 Janssen funded a study that showed 3.8 percent of boys given Risperdal during their clinical trial developed breasts that were either “probably or very likely” caused by the drug. Also in 2001, the Miami Herald reported cases of Risperdal gynecomastia development in boys while in the Florida foster care system who had been given the drug as a pharmaceutical “restraint”.
Between 1999 and 2008, serious adverse event reports of Risperdal use in children numbered over 1200, including 31 deaths. In 2008, the Wall Street Journal reported that Risperdal had been shown to increase prolactin levels (leading to breast development and lactation) and experts reported up to 70 percent of gynecomastia childhood events were found to be caused by Risperdal use. To know more about risperdal gynecomastia lawyer, you can browse the web.
Risperdal Gynecomastia Lawsuits
Risperdal lawsuits also allege that the drug company encouraged off-label prescriptions for children before the breast growth side effect warning was added to the label. According to court documents, J&J encouraged doctors to prescribe Risperdal off-label to treat attention deficit and disruptive behavior and other childhood disorders. Although doctors are allowed to prescribe medicine as they see fit, drug companies can market their products only for uses approved by the FDA.
As of June 2016, about 1,750 Risperdal Gynecomastia lawsuits filed against Janssen Pharmaceuticals are pending in Philadelphia and thousands more Risperdal gynecomastia cases are pending nationwide. Of four Risperdal cases tried to verdict three have resulted in favor of the injured plaintiff. A fifth case ended with some jurors saying there was not enough evidence to directly link Risperdal as the cause of gynecomastia, although they unanimously agreed that J&J should have warned the public that its drug could lead to excessive breast growth.